Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer

Han Byoul Cho, Jae-Hoon Kim

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p50.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value. The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively. By Cox univariate analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard ratio 5 1.47, p50.012). In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalJournal of Histochemistry and Cytochemistry
Volume57
Issue number5
DOIs
Publication statusPublished - 2009 May 1

Fingerprint

Ovarian Neoplasms
Neoplasms
Biomarkers
Serum
Ovarian epithelial cancer
Real-Time Polymerase Chain Reaction
Up-Regulation
Sensitivity and Specificity
Cell Line
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Histology

Cite this

@article{7371d6b96afd430cb7d2649e6afe6d4e,
title = "Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer",
abstract = "We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p50.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value. The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2{\%} and 50.4{\%}, respectively. By Cox univariate analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard ratio 5 1.47, p50.012). In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.",
author = "Cho, {Han Byoul} and Jae-Hoon Kim",
year = "2009",
month = "5",
day = "1",
doi = "10.1369/jhc.2009.953257",
language = "English",
volume = "57",
pages = "513--521",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "5",

}

Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. / Cho, Han Byoul; Kim, Jae-Hoon.

In: Journal of Histochemistry and Cytochemistry, Vol. 57, No. 5, 01.05.2009, p. 513-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer

AU - Cho, Han Byoul

AU - Kim, Jae-Hoon

PY - 2009/5/1

Y1 - 2009/5/1

N2 - We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p50.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value. The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively. By Cox univariate analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard ratio 5 1.47, p50.012). In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.

AB - We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p50.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value. The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively. By Cox univariate analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard ratio 5 1.47, p50.012). In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=66149130751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149130751&partnerID=8YFLogxK

U2 - 10.1369/jhc.2009.953257

DO - 10.1369/jhc.2009.953257

M3 - Article

VL - 57

SP - 513

EP - 521

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 5

ER -